Contact Us
Drug Search Results
More Filters [+]

Amitriptyline

Alternative Names: amitriptyline, amitriptylin, amitryptiline, dwetr, dwetr-10, dwetr-25, dwetr10, dwetr25, amitriptilina, elavil, amitril, amitid, endep, etrafon 2-10, etrafon-a, etrafon-forte, limbitrol ds, triavil 4-10, triavil 4-50, etrafon 2-25, triavil 2-10, triavil 2-25, limbitrol, triavil 4-25
Latest Update: 2024-09-24
Latest Update Note: News Article

Product Description

Amitriptyline is used to treat symptoms of depression. Amitriptyline is in a class of medications called tricyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

Mechanisms of Action: NRI Inhibitor,SRI Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: HolsboerMaschmeyer NeuroChemie
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amitriptyline

Countries in Clinic: Australia, China, Germany, Netherlands, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Dyspareunia

Phase 2: Chronic Pain|Erythromelalgia|Healthy Volunteers|Pelvic Pain|Prostatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EASE

P2

Completed

Erythromelalgia

2024-02-29

CHDR2335

P2

Not yet recruiting

Healthy Volunteers

2024-02-03

ACTRN12619001163190

P3

Recruiting

Dyspareunia

2021-12-31

CTR20200406

P2

Not yet recruiting

Pelvic Pain|Chronic Pain|Prostatitis

None

Recent News Events

Date

Type

Title

09/24/2024

News Article

 AlgoTx Announces "Last Patient Last Visit" in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

06/12/2024

News Article

 Neuropathy Pain Treatment Market size is set to grow by USD 5.84 billion from 2024-2028, Presence of large patient pool of neuropathy pain boost the market, Technavio

06/05/2024

News Article

 Fibromyalgia Treatment Market Size to Worth USD 4.13 Billion by 2032

04/09/2024

News Article

 Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions